SYNOPSYS INC false 0000883241 0000883241 2021-06-17 2021-06-17





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): June 17, 2021




(Exact name of Registrant as specified in charter)




Delaware   000-19807   56-1546236
(State or other jurisdiction
of incorporation)
File Number)
  (I.R.S. Employer
Identification No.)


690 East Middlefield Road
Mountain View, California 94043
(Address of principal executive offices)

Registrant’s telephone number, including area code: (650) 584-5000


(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class




Name of each exchange
on which registered

Common Stock
(par value of $0.01 per share)
  SNPS   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 8.01

Other Events.

On June 17, 2021, Synopsys, Inc. (“Synopsys”) issued a press release announcing that its board of directors (the “Board”) had replenished Synopsys’ existing stock repurchase program up to $500 million. The program authorizes, but does not obligate, Synopsys to purchase up to $500 million of its common stock, and Synopsys’ chief financial officer or Board may suspend or terminate the program at any time at their sole discretion. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits



Exhibit Title

99.1    Press release dated June 17, 2021 announcing the replenishment of Synopsys’ existing stock repurchase program up to $500 million.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


Dated: June 17, 2021     By:  

/s/ John F. Runkel, Jr.

            John F. Runkel, Jr.    
            General Counsel and Corporate Secretary